HANOI, April 26, 2023, Pfizer (Vietnam) Limited Company and the Vietnam National Heart Association signed a memorandum of understanding (MoU) to partner on project “Population Cardiovascular Health” from 2023 to 2025.

Pfizer Vietnam and the Vietnam National Heart Association (VNHA) sign a MoU on “Population Cardiovascular Health” project to improve the healthcare professional’s qualification in the diagnosis and treatment of cardiovascular diseases.

The project marks a critical milestone for a long-term collaboration between the Vietnam National Heart Association and Pfizer in the advanced management of cardiovascular patients and making a positive impact on the community healthcare. The primary goal of this project is to improve the healthcare professional’s qualification in the diagnosis and treatment of cardiovascular diseases in elderly patients, through interdisciplinary coordination and effective use of anticoagulants, especially in the setting of atrial fibrillation and venous thromboembolism.

According to the United Nations Population Fund (UNFPA), Vietnam is one of the most rapidly ageing countries in the world. As the share of the elderly population increased significantly in the period from 2009 to 2019 (from 8.68% to 11.86%), and expected to reach 16.5% in 2029, Vietnam will go into the ageing population by 2036. (1) One of the major medical challenges is cardiovascular disease in the elderly, which has already become quite common. Remarkably, this disease often has comorbidities such as atrial fibrillation with heart failure, atrial fibrillation with kidney failure, and especially stroke. Cardiovascular disease in the elderly heavily affects the patient's quality of life, carries a high risk of mortality, and is a significant economic burden for both individuals and society. (2)

Associate Professor Doctor Pham Manh Hung, the Vice President of the Vietnam National Heart Association, gives a speech at the ceremony.

Associate Professor Doctor Pham Manh Hung, the Vice President of the Vietnam National Heart Association (VNHA), said: “In Vietnam, the current demographic shift towards an older population will be accompanied by a significant increase in the incidence of cardiovascular disease. Cardiovascular disease is currently the most frequently diagnosed disease, remaining the leading cause of death in the elderly. (3) Therefore, it is essential for healthcare professionals to update their knowledge and treatment methods to optimize patient outcomes. We hope that, after this signing ceremony, both parties will create more effective, practical, and sustainable activities, contributing to improving the quality of care and serving patients.”

Darrell Oh, General Director at Pfizer Vietnam, gives a speech at the ceremony.

Darrell Oh, General Director at Pfizer Viet Nam, shared: “For many years, we have been proud to support Vietnam in addressing the burden of cardiovascular disease. This cooperation is a clear demonstration of Pfizer's efforts in effectively combining education and healthcare. Capacity-building programs on cardiovascular disease management as well as the appropriate use of anticoagulants in disease treatment not only help improve the quality of health for the elderly, but also contribute to strengthening the healthcare system in Vietnam. We believe that the positive impact of this cooperation will help accelerate the ability of the healthcare system to cope with the challenges of an aging population.”

Based on the alignment, the VNHA and Pfizer Vietnam signed a memorandum of understanding to collaborate in executing project “Population Cardiovascular Health” to support funding to provide updated scientific evidence and training for healthcare professionals nationwide through activities such as online training series, monthly practical medical newsletters, and intensive hands-on trainings. Each activity has elaborately designed content and is expected to bring many leading domestic and foreign experts to join.

Project “Population Cardiovascular Health” is planned to be implemented over 3 years with the vision of enhancing the capability of approximately 10,000 healthcare professionals nationwide in diagnosing and treating cardiovascular diseases of the elderly.

Source:

1. The completed results of the 2019 Vietnam population and housing census (Tổng điều tra dân số và nhà ở năm 2019).
2. Parag Goyal, Min Ji Kwak, et al. Geriatric Cardiology: Coming of Age. JACC Adv 2022; 1:100070.
3. Daniel E Forman, Michael W Rich, et al. Cardiac care for older adults. Time for a new paradigm. J Am Coll Cardiol 2011;57:1801–10.

About Vietnam National Heart Association (VNHA)
Founded in 1992, the Vietnam National Heart Association (VNHA) is both a non-profit and non-governmental organization for cardiologists, physicians and others with similar interests.

Over the past 30 years of its development, VNHA has become a prestigious professional association at both national and international levels. Currently, VNHA comprises 7 sub-associations, such as the Sub-association of Hypertension; Sub-association of Interventional Cardiology, Sub-association of Echocardiography; Sub-association of Heart Rhythm; Sub-association of Cardiovascular Nursing; Sub-association of Heart Failure; Sub-association of Atherosclerosis. Also, VNHA has branches in territories like Hanoi; Ho Chi Minh City; Hue; Central region; Hai Phong; Khanh Hoa; Quang Ninh. The members of VNHA include cardiologists and healthcare professionals of  related specialties throughout the country and from other nations, e.g. the United States, Germany, France... For more information about the VNHA, please visit the official website: www.vnha.org.vn

Or follow the Association's activities and programs on Facebook at: Facebook.com/vnhacongress and Youtube: youtube.com/@HoiTimMachHocVietNam.


About Pfizer: Breakthroughs That Change Patients’ Lives 
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com. In addition, to learn more, please visit us on www.Pfizer.com and follow us on Twitter at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer. 

Disclosure Notice 
The information contained in this release is as of Arip 26, 2023. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

Media Contact
Minh Ha Ho
+84 987 530 219
[email protected]